![Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press](https://pbs.twimg.com/media/FYn8FMIXoAMvgvr.jpg:large)
Teva Pharmaceuticals on Twitter: "Teva just announced its Q2 2022 financial results. View the press release here: https://t.co/OGECc00hWU Forward-looking statements are subject to the cautionary note included in our Q2 2022 press
![Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) - Drug Target Review Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) - Drug Target Review](http://www.drugtargetreview.com/wp-content/uploads/pain.jpg)
Teva reports positive results from pivotal Phase III study to evaluate hydrocodone bitartrate extended-release tablets (CEP-33237) - Drug Target Review
![Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business Teva Pharmaceutical Industries Ltd.'s Q3 Helped by Actavis Generics Deal -- but Not Quite Enough | Fox Business](https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2018/02/931/506/drugs-with-prescription-pad_large-f2815d7acd668510VgnVCM200000d6c1a8c0____-2.jpg?ve=1&tl=1)